Tiziana Life Sciences shares details of intranasal foralumab study published in PNAS

March 09, 2023 | Last Trade: US$0.78 0.06 -6.85

Tiziana Life Sciences chief medical officer Matthew Davis joins Proactive's Natalie Stoberman to share the latest results from its intranasal foralumab study that's been published in Proceedings of the National Academy of Sciences (PNAS).

Davis says the results show how intranasal foralumab has had similar immune gene expression effects in COVID patients, MS patients and in heathy volunteers that were included in the study. From this study, Davis adds that intranasal foralumab could have a wider opportunity as a treatment for other inflammatory human diseases.

Contact Details

Proactive US

+1 347-449-0879

This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$0.78
Daily Change:	-0.06 -6.85
Daily Volume:	595,134
Market Cap:	US$80.460M

December 17, 2024 Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab December 04, 2024 Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers October 30, 2024 Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million October 30, 2024 Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study August 19, 2024 Tiziana Life Sciences Appoints New Chief Executive Officer LOAD MORE NEWS

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE